Biologics, such as tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors, have revolutionized the management of plaque psoriasis by providing a targeted therapeutic approach that addresses the underlying immunological dysfunction. Here, TNF is linked to psoriasis vulgaris.